

Rosaria Talarico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9225341/publications.pdf>

Version: 2024-02-01

88

papers

1,961

citations

257450

24

h-index

276875

41

g-index

91

all docs

91

docs citations

91

times ranked

3136

citing authors

#	ARTICLE	IF	CITATIONS
1	Classification criteria for Sjogren's syndrome: A critical review. Journal of Autoimmunity, 2012, 39, 9-14.	6.5	122
2	The diagnosis and classification of mixed connective tissue disease. Journal of Autoimmunity, 2014, 48-49, 46-49.	6.5	101
3	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. Clinical Rheumatology, 2016, 35, 1281-1286.	2.2	95
4	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	3.8	91
5	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	3.5	89
6	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	3.5	72
7	COVID-19: the new challenge for rheumatologists. Clinical and Experimental Rheumatology, 2020, 38, 175-180.	0.8	69
8	Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000793.	3.8	66
9	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	2.2	64
10	Behçet's syndrome: a critical digest of the 2014-2015 literature. Clinical and Experimental Rheumatology, 2015, 33, S3-14.	0.8	63
11	Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Research and Therapy, 2015, 17, 277.	3.5	55
12	A Clinical Prediction Rule for Lymphoma Development in Primary Sjögren's Syndrome. Journal of Rheumatology, 2012, 39, 804-808.	2.0	48
13	Symmetric peripheral polyarthritis developed during SARS-CoV-2 infection. Lancet Rheumatology, The, 2020, 2, e518-e519.	3.9	44
14	Relapsing polychondritis: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000788.	3.8	43
15	Behçet's syndrome: a critical digest of the 2013-2014 literature. Clinical and Experimental Rheumatology, 2014, 32, S112-22.	0.8	40
16	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study. Annals of the Rheumatic Diseases, 2020, 79, 1098-1104.	0.9	39
17	Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. Muscle and Nerve, 2016, 54, 666-672.	2.2	38
18	Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000785.	3.8	38

#	ARTICLE	IF	CITATIONS
19	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019, 10, 296.	3.5	35
20	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	8.0	35
21	Sjögren's syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000789.	3.8	34
22	Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. <i>Medicine (United States)</i> , 2015, 94, e1858.	1.0	31
23	Mixed connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000783.	3.8	30
24	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	3.8	28
25	Vitamin D in 'early' primary Sjögren's syndrome: does it play a role in influencing disease phenotypes?. <i>Rheumatology International</i> , 2014, 34, 1159-1164.	3.0	27
26	One year in review 2016: spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 3-17.	0.8	27
27	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 918.	3.5	25
28	Successful Treatment of Refractory Adult-Onset Still Disease With Canakinumab. <i>Journal of Clinical Rheumatology</i> , 2014, 20, 121.	0.9	24
29	One year in review 2017: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 721-734.	0.8	24
30	Ehlers-Danlos syndromes: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000790.	3.8	23
31	The interaction between autoimmune diseases and fibromyalgia: risk, disease course and management. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 1069-1076.	3.0	22
32	Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	22
33	Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 103-108.	1.9	22
34	IgG4-related diseases: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000787.	3.8	21
35	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020, 7, 42.	2.6	21
36	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	3.8	19

#	ARTICLE	IF	CITATIONS
37	Isolated aortitis versus giant cell arteritis: are they really two sides of the same coin?. Clinical and Experimental Rheumatology, 2014, 32, S55-8.	0.8	19
38	Epidemiology and Management of Neuropsychiatric Disorders in Behçet's Syndrome. CNS Drugs, 2015, 29, 189-196.	5.9	18
39	One year in review 2016: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 357-72.	0.8	17
40	One year in review 2016: Behçet's syndrome. Clinical and Experimental Rheumatology, 2016, 34, 10-22.	0.8	16
41	Differential impact of high and low penetrance <i>TNFRSF1A</i> gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. Journal of Leukocyte Biology, 2016, 99, 761-769.	3.3	15
42	COVID-19: the new challenge for rheumatologists. First update. Clinical and Experimental Rheumatology, 2020, 38, 373-382.	0.8	15
43	RareERN Path: a methodology towards the optimisation of patients' care pathways in rare and complex diseases developed within the European Reference Networks. Orphanet Journal of Rare Diseases, 2020, 15, 347.	2.7	12
44	One year in review 2019: Behçet's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 3-17.	0.8	12
45	Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies. RMD Open, 2021, 7, e001914.	3.8	12
46	One year in review: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 102-8.	0.8	11
47	One year in review 2017: Behçet's syndrome. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 3-15.	0.8	11
48	Sexual dysfunction in Behçet's syndrome. Rheumatology International, 2020, 40, 9-15.	3.0	10
49	Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. Clinical and Experimental Rheumatology, 2012, 30, S130-8.	0.8	10
50	Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis. Medicine (United States), 2015, 94, e1170.	1.0	9
51	Development of de novo major involvement during follow-up in Behçet's syndrome. Clinical Rheumatology, 2016, 35, 247-250.	2.2	9
52	Shaping the Future of Rare Diseases after a Global Health Emergency: Organisational Points to Consider. International Journal of Environmental Research and Public Health, 2020, 17, 8694.	2.6	9
53	One year in review 2018: systemic vasculitis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 12-32.	0.8	9
54	One year in review 2018: Behçet's syndrome. Clinical and Experimental Rheumatology, 2018, 36, 13-27.	0.8	9

#	ARTICLE	IF	CITATIONS
55	One year in review 2021: systemic vasculitis. Clinical and Experimental Rheumatology, 2021, 39, 3-12.	0.8	9
56	Rate of serious infections in Behçet's disease patients receiving biologic therapies: a prospective observational study. Clinical Rheumatology, 2013, 32, 1547-1548.	2.2	7
57	Drugs in induction and treatment of idiopathic inflammatory myopathies. Autoimmunity Highlights, 2014, 5, 95-100.	3.9	6
58	Clinical practice guidelines adherence, knowledge and awareness in rare and complex connective tissue diseases across Europe: results from the first ERN ReCONNET survey. RMD Open, 2020, 6, e001344.	3.8	6
59	Behçet's syndrome and psychiatric involvement: is it a primary or secondary feature of the disease?. Clinical and Experimental Rheumatology, 2018, 36, 125-128.	0.8	6
60	One year in review 2020: Behçet's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 3-10.	0.8	6
61	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome. Frontiers in Medicine, 2021, 8, 769870.	2.6	6
62	Systemic vasculitis and the lung. Current Opinion in Rheumatology, 2017, 29, 45-50.	4.3	5
63	Behçet's syndrome and ocular involvement: changes over time. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 86-93.	0.8	5
64	COVID-19: the new challenge for rheumatologists. One year later. Clinical and Experimental Rheumatology, 2021, 39, 203-213.	0.8	5
65	A Clinical Picture of the Visual Outcome in Adamantiades-Behçet's Disease. BioMed Research International, 2015, 2015, 1-9.	1.9	4
66	One year in review 2019: vasculitis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 3-19.	0.8	4
67	Being a caregiver of a Behçet's syndrome patient: challenges and perspectives during a complex journey. Orphanet Journal of Rare Diseases, 2021, 16, 436.	2.7	3
68	One year in review 2017: systemic vasculitis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 5-26.	0.8	3
69	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clinical and Experimental Rheumatology, 2022, 40, 103-112.	0.8	3
70	One year in review 2020: vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 3-14.	0.8	2
71	One year in review 2021: systemic vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 3-12.	0.8	2
72	COVID-19 mRNA vaccine booster in patients with autoimmune rheumatic diseases. Rheumatology, 2022, 61, e328-e330.	1.9	2

#	ARTICLE	IF	CITATIONS
73	Rate of serious infections in patients with rheumatoid arthritis receiving tumor necrosis factor (TNF)-alpha antagonist: A prospective observational study. Joint Bone Spine, 2014, 81, 378-379.	1.6	1
74	COVID-19: the new challenge for rheumatologists. One year later. Clinical and Experimental Rheumatology, 2021, 39, 203-213.	0.8	1
75	One year in review 2021: Behçet's syndrome. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 3-13.	0.8	1
76	Empowering rare disease patients through patient education: the new BehçetTalk programme. BMC Rheumatology, 2022, 6, 17.	1.6	1
77	Systemic vasculitis: one year in review 2022. Clinical and Experimental Rheumatology, 2022, 40, 673-687.	0.8	1
78	An Opportunity to Harmonise the Approach to Patients' Care Pathways for Rare and Complex Diseases: RarERN Path, 0, 2, .		1
79	Taux d'infections sévères chez les patients atteints de polyarthrite rhumatoïde recevant une biothérapie anti-TNF alpha: Étude observationnelle prospective. Commentaire de l'article de Che et al.. Revue Du Rhumatisme (Edition Francaise), 2015, 82, 66-67.	0.0	0
80	Morphologic ultrasonography of the temporal artery for diagnosis of giant cell arteritis: Brief report. Modern Rheumatology, 2019, 29, 717-719.	1.8	0
81	Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center. Clinical Rheumatology, 2019, 38, 2917-2923.	2.2	0
82	AB0618...A SNAPSHOT OF DISEASE ACTIVITY IN PATIENTS WITH BEHCET'S SYNDROME: PREDICTIVE FACTORS AND RELATIONSHIP WITH QUALITY OF LIFE. , 2019, , .		0
83	FRI0607...IDENTIFICATION OF UNMET NEEDS RELATED TO RARE AND COMPLEX CONNECTIVE TISSUE AND MUSCULOSKELETAL DISEASES (RCTDS) ACROSS EU: THE EXPERIENCE OF THE ERN RECONNET. , 2019, , .		0
84	Skin Manifestations and Cryoglobulinemia. , 2014, , 329-335.		0
85	Behçet Disease. , 2016, , 225-232.		0
86	Cardiometabolic risk and subclinical vascular damage assessment in idiopathic inflammatory myopathies: a challenge for the clinician. Clinical and Experimental Rheumatology, 2019, 37, 1036-1043.	0.8	0
87	Adherence to treatment in Behçet's syndrome: a multi-faceted issue. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 88-93.	0.8	0
88	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0